• A 2010 paper on the tumor-suppressor protein Kibra and its role in Hippo signaling (DOI: 10.1016/j.devcel.2010.01.014) was circulated as a biology reference for open-source longevity research.  
• Participants discussed using Apple Watch 3 continuous HR logging, HRV biofeedback (PMC4104929), theanine, and caffeine elimination to manage resting heart rates of 90–100 bpm; one user noted that 50 mg Vyvanse raises HR only 5–10 bpm while a single cup of coffee adds 10–20 bpm.  
• The ColumbiaOpenSourceUltrasound GitHub organization was highlighted as an active open-hardware resource, and the 2017 Science Advances paper “Compressive 3D ultrasound imaging using a single sensor” was shared as evidence that time-reversal reconstruction with one transducer can replace phased arrays.  
• A long-term vision was articulated for low-cost, high-frequency ultrasound arrays: repurposing inkjet MEMS printheads (≈10 µm nozzles) to fabricate phased-array transducers for non-invasive tumor ablation and low-power neural stimulation.  
• MIT’s video-magnification algorithm (http://people.csail.mit.edu/mrub/vidmag/) was proposed as an AR headset filter to visualize micro-motions and color shifts in real time, with demos at https://www.youtube.com/watch?v=e9ASH8IBJ2U and https://www.youtube.com/watch?v=EhZXDgG9oSk.  
• Historical longevity ventures were revisited: Clonaid/Stemaid’s 1996-era cloning claims and their RMX2010 low-voltage electroporator, plus anecdotal evidence that billionaire funders prioritize biological immortality over cryonics or mind-uploading.  
• A mass-autopsy initiative was advocated: comprehensive post-mortem analyses on one million elderly donors to create a high-resolution atlas of age-related pathology and accelerate aging research.  
• An in-vivo bioreactor concept was floated: using the circulatory systems of near-death elderly patients as continuous-flow reactors for directed evolution of “young blood” rejuvenation factors via inline mutagenesis and selection.  
• Xenotransplantation was projected to deliver immuno-compatible pig-to-human organ transplants within 5–10 years if current funding levels continue.